Today: 30 April 2026
Nvidia stock price rises today as China signals H200 AI chip orders could restart (NVDA)
23 January 2026
2 mins read

Nvidia stock price rises today as China signals H200 AI chip orders could restart (NVDA)

New York, January 23, 2026, 09:36 AM ET — Regular session underway.

  • Nvidia shares climbed in early trading following reports that Chinese regulators instructed leading tech companies to get ready to order its H200 AI chips
  • The shift unfolds amid investor concerns over export-policy risks and the Federal Reserve’s decision looming next week
  • Nvidia will release its quarterly earnings on Feb. 25

NVIDIA Corp shares climbed on Friday following a report that Chinese authorities instructed Alibaba, Tencent, and ByteDance to start preparing orders for Nvidia’s H200 AI chips. Investors saw this as a sign of progress toward reopening the crucial Chinese market. The stock gained 0.8% to $184.84, after earlier jumping nearly 3%.

This report is significant because Nvidia’s sales in China have been unpredictable, caught in the crossfire of U.S. export restrictions and Beijing’s scrutiny over advanced chip destinations. Traders want something solid—an order, a confirmed shipment date—anything that shifts “maybe” into actual revenue.

The tape was unsettled as chip stocks showed a mixed picture, with Intel slipping on a disappointing outlook. Investors brace for a busy week loaded with earnings reports and a Fed meeting. “Guidance now is more critical than ever,” noted Peter Cardillo, chief market economist at Spartan Capital Securities. Reuters

Earlier this month, the Trump administration formally approved China-bound H200 sales, but with strings attached: third-party testing before export and caps tied to U.S. sales, per the new rules. Nvidia hailed the regulation as “a thoughtful balance that is great for America.” Seaport Research’s Jay Goldberg, however, dismissed it as “a Band-Aid,” cautioning that enforcing these measures could get tricky. Reuters

Beijing’s position remains unclear. Nvidia CEO Jensen Huang is set to visit China in late January, coinciding with Lunar New Year festivities, Bloomberg reported earlier this week. The trip aims to help Nvidia regain ground in the Chinese market; the company declined to comment.

Still, the downside remains a real risk. That initial approval might hit a wall, Washington could crank up the pressure, and new restrictions could tighten around Chinese buyers—limiting who accesses the chips and how they use them.

The next clear trigger is in Washington, not Santa Clara. The Fed convenes Jan. 27-28, with its policy call set for 2 p.m. ET on Jan. 28, then a press briefing at 2:30 p.m.

Next week’s earnings season will put the broader “AI trade” under the microscope. Around 20% of the S&P 500 is set to report, and investors are eager to see AI spending translate into actual profits, not just capital expenditures. “At the end of the day, earnings are the driver,” said Chris Galipeau, senior market strategist at Franklin Templeton. Reuters

Nvidia’s next key date is Feb. 25, when it’s set to release its fourth-quarter fiscal 2026 results, per the company’s investor calendar.

Traders will be closely tracking if “prepare orders” shift into actual purchase orders and if clearer timing on shipments to China comes through. The Fed’s decision on Jan. 28 looms as the immediate challenge, with Nvidia’s update on Feb. 25 set to be the next major event for NVDA.

Stock Market Today

  • Eli Lilly (LLY) Shares Drop 7.6% in Week, DCF Model Suggests 40% Undervaluation
    April 29, 2026, 11:18 PM EDT. Eli Lilly's (LLY) stock price has dropped 7.6% in the past week, down 21.2% year to date despite a strong 3-year return exceeding 100%. The recent pullback prompts questions on valuation. A Discounted Cash Flow (DCF) analysis, which forecasts future free cash flows discounted to present value, estimates the stock's intrinsic value at $1,427.87, about 40.4% above the current $851.21 share price. This suggests the shares might be undervalued despite their recent decline. Conversely, Eli Lilly's price-to-earnings (P/E) ratio stands at 36.9, representing a premium compared to the pharmaceutical industry average of 15.9 and peers at 19.2, indicating the market prices in higher growth expectations or lower risk. Investors face a mixed picture: a substantial discount on cash flow metrics but a premium relative to earnings multiples.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap
Previous Story

Novo Nordisk stock price jumps before the bell as Wegovy pill prescriptions leap

Nvidia stock climbs as China order signal lifts AI chips; Intel slide keeps traders wary
Next Story

Nvidia stock climbs as China order signal lifts AI chips; Intel slide keeps traders wary

Go toTop